SCHEDULE 13G/A: Amundi and Amundi Asset Management US Report 4.8% Beneficial Ownership in Sanofi

Amundi and its subsidiary, Amundi Asset Management US, Inc., have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 4.8% in Sanofi's common stock and American Depositary Receipts as of March 31, 2025.

Summary

• Amundi and Amundi Asset Management US, Inc. collectively beneficially own 59,281,552 shares of Sanofi's Common Stock and American Depositary Receipts.
• This aggregate amount represents 4.8% of Sanofi's class of securities.
• Both reporting persons, Amundi and Amundi Asset Management US, Inc., are organized under the laws of the Republic of France.
• Amundi and Amundi Asset Management US, Inc. hold shared voting power over 29,656,486 shares.
• They hold shared dispositive power over 59,281,552 shares.
• Amundi does not have voting rights on 24,023,229 shares, which are held through a FCPE (Fonds Commun de Placement d'Enterprise), an investment vehicle established under French law solely dedicated to Sanofi group's employee shareholding.
• The voting rights for the FCPE shares are exercised by its supervisory Board, where employee representatives hold the majority.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

This document is a beneficial ownership report and does not contain forward-looking statements or guidance regarding Sanofi's future performance or outlook.

Management Comments

• John M. Malone, Chief Compliance Officer for Amundi and Amundi Asset Management US, Inc., certified that 'to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

This filing reflects a routine disclosure of institutional ownership by a major asset manager, Amundi, in a global pharmaceutical company, Sanofi. It provides insight into the passive investment holdings of large financial institutions within the healthcare sector, rather than indicating specific industry trends or competitive shifts.

Stakeholder Impact

• Employees of Sanofi are impacted by the FCPE structure, which allows them to participate in stock purchase plans and collectively exercise voting rights through a supervisory board where employee representatives hold the majority. This arrangement ensures employee voice in governance related to their shareholdings.

Key Dates

Keywords

Sanofi, Amundi, Amundi Asset Management US, Schedule 13G, Beneficial Ownership, Common Stock, American Depositary Receipts, FCPE, Employee Shareholding, Institutional Investor, Asset Management